Please do not leave this page until complete. This can take a few moments.
The former supervisory pharmacist of the Framingham-based New England Compounding Center connected with a 2012 nationwide meningitis outbreak killing 64 and infecting almost 800 others was sentenced to eight years in prison Wednesday.
Glenn Chin, 49, of Canton, is also subject to two years of supervised release, forfeiture and restitution in an amount that will be determined later.
He was convicted in October on 77 counts, including charges of racketeering, racketeering conspiracy, mail fraud and introduction of misbranded drugs into interstate commerce with the intent to defraud and mislead.
He was, however, acquitted of murder charges, according to court records.
In 2012, 793 patients were diagnosed with a fungal infection after receiving injections of preservative-free methylprednisolone acetate manufactured by the New England Compounding Center. Of those patients, 64 died across nine states, according to the Centers for Disease Control.
According to the U.S. Attorney's Office, Chin manufactured three lots of the contaminated drugs, compromising 17,000 vials of medication.
"In doing so, Chin ignored NECC's own drug formulation worksheets and standard operating procedures," the office said.
Chin's sterilization was substantially inadequate, and he failed to validate or verify the sterilization process at all, the office said.
He directed the medicine to be shipped to NECC customers nationwide prior to receiving test results confirming their safety and directed pharmacy technicians to mislabel drugs to conceal the practice, the office said.
Under his watch, drugs were compounded with expired ingredients, and he directed the forging of cleaning logs and ignored mold and bacteria found in clean rooms.
With other co-conspirators, Chin utilized a technician whose license had been revoked by the state Board of Pharmacy and concealed the technician's presence from state regulators.
Stay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Sign upWorcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
SubscribeWorcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
See Digital EditionStay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
Worcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments